Market news

Wells Fargo has put a number on the damage Boston Scientific Corporation’s (NYSE:BSX) August cybersecurity incident could do to its third-quarter results, which comes up to roughly $300 million in sales and about $0.13 per share in earnings. Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Boston Scientific to $48 from $50 […]

Oppenheimer has become considerably more cautious on Boston Scientific Corporation (NYSE:BSX), but not cautious enough to abandon its bullish rating. Analyst Suraj Kalia lowered the firm’s price target on Boston Scientific to $65 from $85 on September 21, ahead of the company’s quarterly results, while maintaining an Outperform rating. Kalia is also reducing Oppenheimer’s fiscal […]

Boston Scientific recalls Imager II Angiographic Catheters over tip detachment defect. Learn about patient risks & FDA safety updates.

According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Boston Scientific (NYSE: BSX) has started a voluntary global recall of its StoneSmart Connect Console over a power adapter safety issue. The company is informing hospitals and healthcare providers worldwide about the recall and advising on identification and return of affected units. Arthur C. Butcher, who oversees key endoscopy and urology portfolios, has notified Boston Scientific of his decision to retire. The recall of StoneSmart Connect and Arthur C. Butcher's retirement only capture...

Boston Scientific has seen its share price fall sharply over the past year, which naturally raises a question for investors who care about fundamentals. Are the cash flows that the business can generate enough to support where the stock trades today, or has sentiment moved further than the underlying economics justify? The share price has declined 55.4% over the past year, so the recent slide puts the focus squarely on whether that move lines up with the cash that Boston Scientific can...

Boston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%. The market repriced Boston Scientific's growth rate after management concentrated its guidance cut in two core product lines.

Boston Scientific (NYSE:BSX) has initiated a voluntary global recall of its LUX-Dx Insertable Cardiac Monitor System and software over atrial fibrillation Burden Alert delays. The recall targets multiple versions of LUX-Dx hardware and associated software that may postpone detection alerts for atrial arrhythmias used in patient monitoring. The US FDA has taken enforcement interest in the action, underscoring regulatory scrutiny of the cardiac monitoring platform and its alert...

An analysis of recent filings from American politicians shows that Accenture (NYSE: ACN) and Boston Scientific (NYSE: BSX) saw an uptick in purchases from notable politicians. Rep. Gilbert Ray Cisneros, Jr. (D-CA) bought Boston Scientific shares, according to a filing earlier this month. The trade was made on August 18, 2026. Rep. Ro Khanna (D-CA) […]

Detailed price information for Medtronic Inc (MDT-N) from The Globe and Mail including charting and trades.

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

Boston Scientific Corporation (NYSE:BSX) fell 2.3% in early trading on September 8, 2026, after disclosing that an August 25 cyberattack disrupted manufacturing and shipping. The company stated it is unlikely to meet its previously issued third-quarter and full-year 2026 guidance for net sales and adjusted earnings per share. Though operations have since resumed, the incident […]

Boston Scientific (BSX) reached $43.1 at the closing of the latest trading day, reflecting a -4.14% change compared to its last close.

Boston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "mater

Boston Scientific said Tuesday a cybersecurity incident is likely to have a material impact on its third-quarter and full-year results.

BSX's 2026 outlook weakens as WATCHMAN and EP face pressure, but seven launches and cost savings are likely to fuel recovery by 2028.

Sept 8 (Reuters) - Boston Scientific said on Tuesday it no longer expects to meet its previously issued third-quarter and full-year 2026 sales and adjusted profit forecasts, after a cybersecurity

These are the stocks posting the largest moves premarket.

Boston Scientific warns cybersecurity incident may hit Q3/full-year 2026 results; shares slide as guidance at risk.

Boston was hit by a cyberattack on 25 August that caused widespread disruption to its global operations.

Boston Scientific (BSX) stock gains as the company has begun restoring shipping capabilities after a cybersecurity incident last week. Read more here.

BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.

The company is working through a backlog after the cyberattack hampered manufacturing, order processing and shipping.